Related Experiment Video
Updated: Dec 25, 2025
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
T Regulatory Cell Frequency During Maintenance Phase Chemotherapy for Pediatric Acute Lymphoblastic Leukemia
Marina Nayeli Medina-Rosales1, Susana Godina-González, Mariana Haydee García-Hernández
1Unidad de Investigación Biomédica de Zacatecas, Delegación Zacatecas. Instituto Mexicano del Seguro Social, IMSS.
Background:
Drugs used in cancer treatment specifically kill T regulatory cells.
Objective:
To determine different phenotypes of T regulatory cells during the maintenance phase chemotherapy for pediatric acute lymphoblastic leukemia (ALL).
Materials:
We evaluated the percentages of regulatory T cells by flow cytometry. Soluble CTLA-4 (sCTLA-4) in plasma was evaluated by ELISA assay.
Results:
Increased percentages of CD4+CD25+ T cells, CD4+CD39+ T cells, CD4+Foxp3+ T cells, and CD4+CD25High T cells were observed in children with ALL in comparison to healthy controls. In addition, the ALL patients with >12 months of therapy showed increased CD4+CD39+ T cells compared to the ALL patients with ≤12 months and healthy controls. Similarly, the CD4+CD25+ T cells and CD4+Foxp3+ T cells increased according to maintenance therapy time.
Conclusion:
Our results showed increased percentages of regulatory T cells in pediatric ALL patients despite chemotherapy, which might be compromising the anti-leukemic cellular immune response.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
01:19Multipotency of Hematopoietic Stem Cells
01:15Differentiation of Common Myeloid Progenitor Cells